Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy

Research output: Contribution to journalReview article

18 Scopus citations


Increasing use of antiplatelet therapies is associated with increasing GI complications, such as ulceration and GI bleeding. Identification of high-risk patients and, in such patients, incorporation of strategies to reduce their GI risk would be clinically prudent. After assessment and treatment of H pylori in patients with prior ulcer or GI bleeding histories, further reduction in GI risk in other high-risk patients who require antiplatelet agents is primarily accomplished by prescribing drugs that when coadministered with antiplatelet agents protect against mucosal ulceration, primarily proton pump inhibitors (PPIs). However, observational studies indicate a higher cardiovascular event rate in patients taking PPIs along with clopidogrel and aspirin compared with that of patients undergoing dual antiplatelet therapy without PPIs. Whether concurrent use of a PPI with clopidogrel represents a safety concern or not is currently being evaluated by the US Food and Drug Administration. Until more specific regulatory guidance is available, current recommendations are that patients taking both PPIs and clopidogrel concurrently should probably continue to do so until more data become available.

Original languageEnglish (US)
Pages (from-to)289-303
Number of pages15
JournalGastroenterology Clinics of North America
Issue number2
StatePublished - Jun 1 2009


  • Antiplatelet therapy
  • Aspirin
  • Clopidogrel prasugrel
  • Gastrointestinal bleeding
  • Helicobacter pylori
  • Risk
  • Thienopyridines

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy'. Together they form a unique fingerprint.

  • Cite this